<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04063579</url>
  </required_header>
  <id_info>
    <org_study_id>UW18-022</org_study_id>
    <nct_id>NCT04063579</nct_id>
  </id_info>
  <brief_title>Cardiac Magnetic Resonance Assessment for Heart Failure With Preserved Ejection Fraction</brief_title>
  <official_title>Cardiac Magnetic Resonance Assessment for Heart Failure With Preserved Ejection Fraction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Hong Kong</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective study that aims to define the utility of cardiac magnetic resonance&#xD;
      feature tracking (CMR-FT) as a non-invasive quantification tool to assess diastolic&#xD;
      functionality in patients with Heart Failure with preserved ejection fraction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite the increasing prevalence and poor prognosis of HFpEF worldwide, it is facing&#xD;
      diagnostic challenges due to its non-specific clinical manifestations. Currently,&#xD;
      echocardiography serves as the main diagnostic tool, but alternatives are limited to less&#xD;
      preferred invasive procedures in most clinical situations.&#xD;
&#xD;
      It is therefore proposed to investigate HFpEF using cardiovascular magnetic resonance imaging&#xD;
      (CMR), as an alternative non-invasive diagnostic tool which carries lower risk than invasive&#xD;
      procedures.&#xD;
&#xD;
      The study aims to: (1) access the utility of CMR-FT as a new indicator to diagnose diastolic&#xD;
      dysfunction by differentiating HFpEF patients from non-HFpEF patient and normal volunteers.&#xD;
      (2) Compare accuracy of CMR-FT to CMR tagging and phase contrast imaging.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Actual">September 29, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Accuracy of feature tracking diastolic strain rate to diagnose diastolic dysfunction by differentiating HFpEF patients from the non-HFpEF patients and normal volunteers</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complication rate of cardiac catheterisation</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unexpected findings by CMR (eg. Cardiac amyloidosis)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">172</enrollment>
  <condition>Heart Failure With Preserved Ejection Fraction</condition>
  <arm_group>
    <arm_group_label>Patients with heart failure with preserved ejection fraction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-heart failure patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Cardiac Magnetic Resonance, Echocardiogram, Blood investigation (NT-proBNP), cardiac catheterization</intervention_name>
    <description>Imaging, blood tests, LV pressure measurement</description>
    <arm_group_label>Non-heart failure patients</arm_group_label>
    <arm_group_label>Patients with heart failure with preserved ejection fraction</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Cardiac Magnetic Resonance, Echocardiogram, Blood investigation (NT-proBNP)</intervention_name>
    <description>Imaging and Blood tests</description>
    <arm_group_label>Normal Volunteers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients presenting with symptoms and signs suggestive of HFpEF&#xD;
&#xD;
          -  Patients undergoing coronary catheterisation for stable chest pain with no evidence of&#xD;
             diastolic dysfunction, heart failure, infarct, left ventricular ejection fraction &lt;50%&#xD;
             or significant coronary artery disease (ie. &gt;50% narrowing of one or more coronary&#xD;
             arteries)&#xD;
&#xD;
          -  Volunteers must be asymptomatic with no cardiac risk factors and no previous cardiac&#xD;
             history&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients suspected to have HFpEF but echocardiography and/or invasive pressure&#xD;
             measurements do not confirm diagnosis of HFpEF.&#xD;
&#xD;
          -  Significant underlying ischaemia based on clinical history and non-invasive imaging or&#xD;
             catheter coronary angiography if indicated.&#xD;
&#xD;
          -  Contraindication to CMR study&#xD;
&#xD;
          -  Estimated glomerular filtration rate &lt;30 ml/min/1.73 m2&#xD;
&#xD;
          -  More than moderate valvular disease&#xD;
&#xD;
          -  Severe pulmonary disease (ie. FEV1 &lt;- 50% predicted)&#xD;
&#xD;
          -  Cardiomyopathy&#xD;
&#xD;
          -  Constrictive pericarditis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The University of Hong Kong</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>August 16, 2019</study_first_submitted>
  <study_first_submitted_qc>August 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2019</study_first_posted>
  <last_update_submitted>September 30, 2021</last_update_submitted>
  <last_update_submitted_qc>September 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Natriuretic Peptide, Brain</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

